Join
Live feed
·
PRReleasevia Quantisnow
SciSparc Ltd. logo
Clearmind Medicine Inc. logo

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

ByQuantisnow·Wall Street's wire, on your screen.
SPRC· SciSparc Ltd.CMND· Clearmind Medicine Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SPRC (SciSparc Ltd.), CMND (Clearmind Medicine Inc.) and more on Quantisnow.

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation | Quantisnow